Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors

Open access
Mazzaferro, V, Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., Regalia, E., Spreafico, C., Gangeri, L., Buzzoni, R., de Braud, F.G., De Feo, T., Mariani, L.·2016·American Journal of Transplantation

Abstract

Selection criteria and benefit of liver transplantation for hepatic metastases from neuroendocrine tumors (NETs) remain uncertain. Eighty-eight consecutive patients with metastatic NETs eligible for liver transplantation according to Milan-NET criteria were offered transplant (n = 42) versus nontransplant options (n = 46) depending on list dynamics, patient disposition, and age. Tumor burden between groups did not differ. Transplant patients were younger (40.5 vs. 55.5 years; p < 0.001). Long-term outcomes were compared after matching between groups made on multiple Cox models adjusted for propensity score built on logistic models. Survival benefit was the difference in mean survival between transplant versus nontransplant options. No patients were lost or died without recurrence. Median follow-up was 122 months. The transplant group showed a significant advantage over nontransplant strategies at 5 and 10 years in survival (97.2% and 88.8% vs. 50.9% and 22.4%, respectively; p < 0.001) and time-to-progression (13.1% and 13.1% vs. 83.5% and 89%; p < 0.001). After adjustment for propensity score, survival advantage of the transplant group was significant (hazard ratio = 7.4; 95% confidence interval (CI): 2.4-23.0; p = 0.001). Adjusted transplant-related survival benefit was 6.82 months (95% CI: 1.10-12.54; p = 0.019) and 38.43 months (95% CI: 21.41-55.45; p < 0.001) at 5 and 10 years, respectively. Liver transplantation for metastatic NETs under restrictive criteria provides excellent long-term outcome. Transplant-related survival benefit increases over time and maximizes after 10 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ajt.13831

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 220

Metadata

Authors
Mazzaferro, V, Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., Regalia, E., Spreafico, C., Gangeri, L., Buzzoni, R., de Braud, F. G., De Feo, T., & Mariani, L.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2016-10
Volume
16
Issue
10
Pages
2892-2902
ISSN
1600-6135 (ISSN-L)
OpenAlex
W2343289081
Cited by
220
References
2
FWCI
12.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1111/ajt.13831
The paper
Mazzaferro, V, Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., Regalia, E., Spreafico, C., Gangeri, L., Buzzoni, R., de Braud, F. G., De Feo, T., & Mariani, L. (2016). The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. American Journal of Transplantation. https://doi.org/10.1111/ajt.13831

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.